<SEC-DOCUMENT>0001493152-23-033356.txt : 20230921
<SEC-HEADER>0001493152-23-033356.hdr.sgml : 20230921
<ACCEPTANCE-DATETIME>20230921163939
ACCESSION NUMBER:		0001493152-23-033356
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230915
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230921
DATE AS OF CHANGE:		20230921

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANGOCEUTICALS, INC.
		CENTRAL INDEX KEY:			0001938046
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				873841292
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41615
		FILM NUMBER:		231269509

	BUSINESS ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248
		BUSINESS PHONE:		(833) 626-4679

	MAIL ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:MGRX="http://mangorx.com/20230915">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_MGRX_mangorx.com_20230915 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20230915_20230915 -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001938046 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2023-09-15" name="dei:EntityCentralIndexKey">0001938046</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-09-15" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="mgrx-20230915.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2023-09-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-15</xbrli:startDate>
        <xbrli:endDate>2023-09-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90D_edei--DocumentType_c20230915__20230915_zrhz4tDVfpRj"><ix:nonNumeric contextRef="AsOf2023-09-15" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of Earliest Event Reported): <b><span id="xdx_90D_edei--DocumentPeriodEndDate_c20230915__20230915_z7MktrRh5AD9"><ix:nonNumeric contextRef="AsOf2023-09-15" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 15, 2023</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_902_edei--EntityRegistrantName_c20230915__20230915_zkR2hJy1wnyc"><ix:nonNumeric contextRef="AsOf2023-09-15" name="dei:EntityRegistrantName">MANGOCEUTICALS,
INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20230915__20230915_zmEXIbY3sqR4"><ix:nonNumeric contextRef="AsOf2023-09-15" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Texas</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityFileNumber_c20230915__20230915_zClDa59VXNpk"><ix:nonNumeric contextRef="AsOf2023-09-15" name="dei:EntityFileNumber">001-41615</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20230915__20230915_zn0wUkpTAxmk"><ix:nonNumeric contextRef="AsOf2023-09-15" name="dei:EntityTaxIdentificationNumber">87-3841292</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
                                            or other<br />
 jurisdiction of </b></span><b>incorporation)</b></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission<br />
                                            </b></span><b>File Number)</b></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS
Employer<br />
</b></span><b>Identification No.)</b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20230915__20230915_zhYhgnfHJe6k"><ix:nonNumeric contextRef="AsOf2023-09-15" name="dei:EntityAddressAddressLine1">15110
                                            N. Dallas Parkway</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressAddressLine2_c20230915__20230915_zXLryJ0Vpu3l"><ix:nonNumeric contextRef="AsOf2023-09-15" name="dei:EntityAddressAddressLine2">Suite 600</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressCityOrTown_c20230915__20230915_zSfmk2kF8eU"><ix:nonNumeric contextRef="AsOf2023-09-15" name="dei:EntityAddressCityOrTown">Dallas</ix:nonNumeric></span>,
    <span id="xdx_902_edei--EntityAddressStateOrProvince_c20230915__20230915_zyFnxNiqTLhf"><ix:nonNumeric contextRef="AsOf2023-09-15" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Texas</ix:nonNumeric></span></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityAddressPostalZipCode_c20230915__20230915_zxrZ9TiF69eg"><ix:nonNumeric contextRef="AsOf2023-09-15" name="dei:EntityAddressPostalZipCode">75248</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
    of principal executive offices)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Zip
    Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span id="xdx_909_edei--CityAreaCode_c20230915__20230915_zdcodCJj1sQb"><ix:nonNumeric contextRef="AsOf2023-09-15" name="dei:CityAreaCode">(214)</ix:nonNumeric></span> <span id="xdx_902_edei--LocalPhoneNumber_c20230915__20230915_z35wnJrFqJE7"><ix:nonNumeric contextRef="AsOf2023-09-15" name="dei:LocalPhoneNumber">242-9619</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--WrittenCommunications_c20230915__20230915_zWanpe0Ovsnd"><ix:nonNumeric contextRef="AsOf2023-09-15" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--SolicitingMaterial_c20230915__20230915_ze8cKsHQmsF"><ix:nonNumeric contextRef="AsOf2023-09-15" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--PreCommencementTenderOffer_c20230915__20230915_zfN6wdcesNIi"><ix:nonNumeric contextRef="AsOf2023-09-15" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--PreCommencementIssuerTenderOffer_c20230915__20230915_zRyOz39nWkwc"><ix:nonNumeric contextRef="AsOf2023-09-15" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20230915__20230915_z03V4rAJp2d1"><ix:nonNumeric contextRef="AsOf2023-09-15" name="dei:Security12bTitle">Common
    Stock, $0.0001 Par Value Per Share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--TradingSymbol_c20230915__20230915_z5ePExy53lxi"><ix:nonNumeric contextRef="AsOf2023-09-15" name="dei:TradingSymbol">MGRX</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--SecurityExchangeName_c20230915__20230915_zmeBJyLiHlMg"><ix:nonNumeric contextRef="AsOf2023-09-15" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The
                                            NASDAQ Stock Market LLC</ix:nonNumeric></span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Nasdaq
    Capital Market)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company&#160;<span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20230915__20230915_zrxdX5ZoIIIk"><ix:nonNumeric contextRef="AsOf2023-09-15" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span id="xdx_902_edei--EntityExTransitionPeriod_c20230915__20230915_zSVsgyVctsjd"><ix:nonNumeric contextRef="AsOf2023-09-15" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2023, Mangoceuticals, Inc. (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;, &#8220;<span style="text-decoration: underline">we</span>&#8221; and &#8220;<span style="text-decoration: underline">us</span>&#8221;) entered
into (1) a Consulting Agreement (the &#8220;<span style="text-decoration: underline">Consulting Agreement</span>&#8221;) with Epiq Scripts, LLC (&#8220;<span style="text-decoration: underline">Epiq Scripts</span>&#8221;),
which is 51%-owned by Jacob D. Cohen, our Chairman and Chief Executive Officer, who also serves as the Manager of Epiq Scripts; and (2)
a First Addendum to Master Services Agreement with Epiq Scripts (the &#8220;<span style="text-decoration: underline">First Amendment</span>&#8221;), which amended that certain
Master Services Agreement dated September 1, 2022, by and between the Company and Epiq Scripts (the &#8220;<span style="text-decoration: underline">MSA</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Consulting
Agreement</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Consulting Agreement, Epiq Scripts agreed to provide pharmacy consulting services in connection with the Company&#8217;s global
expansion efforts, and as reasonably requested by the Company, during the term of the agreement, which is for five years, unless otherwise
earlier terminated (a) due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice
thereof; (b) the mutual agreement of the parties; or (c) the date that Epiq Scripts provides the Company written notice of termination,
which may be at any time and for any reason.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for agreeing to provide the services under the agreement, the Company agreed to pay Epiq Scripts (1) a one-time payment
of $65,000, payable within ten days of the entry into the agreement; and (2) a set fee, payable for each prescription drug pill sold
by the Company for cash, to the extent such pill must be prescribed by a medical doctor, or sold through retail pharmacies over the counter,
in jurisdictions where a doctor&#8217;s prescription is not required for the sale of such drugs, and sold in a Territory (defined below),
which consideration per pill decreases each year that the agreement is in effect, and is only payable for the first five years of the
agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
First Amendment further provides that no payments are due for the sale of any Prescription Pills until the First Sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Consulting Agreement, (a) &#8220;<span style="text-decoration: underline">Territory</span>&#8221; means worldwide, except for the United States, including its territories
and possessions and the District of Columbia; and (b) &#8220;<span style="text-decoration: underline">First Sale</span>&#8221; means the date that the first commercial sale of
Prescription Pills occurs in the Territory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
payments are also required to be offset equitably for any Prescription Pill sold which is later refunded, charged back, returned, or
reimbursed to a purchaser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement includes customary representations of the parties, confidentiality and non-solicitation provisions, rights of Epiq Scripts
to audit the sales of Prescription Pills, subject to certain limitations and requirements, and the requirement that the Company reimburse
certain expenses of Epiq Scripts, subject to certain limitations and pre-approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">First
Amendment to MSA</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously reported, on September 1, 2022, and effective on August 30, 2022, we entered into the MSA with Epiq Scripts. Pursuant to the
MSA and a related statement of work (&#8220;<span style="text-decoration: underline">SOW</span>&#8221;), Epiq Scripts agreed to provide pharmacy and related services to us, we
agreed to exclusively use Epiq Scripts as the provider of online fulfillment, specialty compounding, packaging, shipping, dispensing
and distribution services relating to products sold exclusively via our website, that may be prescribed as part of a telehealth consultation
on our platform, during the term of the MSA, so long as Epiq Scripts complies with the terms of the MSA. The agreement also includes
a 30-day right of first refusal for Epiq Scripts to provide pharmacy services for any new product that Mango may introduce during the
term of the MSA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MSA has a term of five years, automatically renewable for additional one-year terms thereafter unless either party provides the other
notice of termination at least 90 days prior to the date of automatic renewal. The MSA can be terminated (i) upon breach of the agreement
by the other party, subject to a 90-day cure right, (ii) if a party enters into bankruptcy or fails to pay its debts as they become due,
or (iii) if Epiq Scripts becomes unable to perform the services covered by the MSA and any statements of work associated therewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the First Amendment, the parties agreed to amend the MSA to include certain Right of first negotiation rights and right of first refusal
rights (each as discussed below). Additionally, the First Amendment provides for certain rights to Epiq Scripts in the event that the
Company seeks to obtain pharmaceutical services in connection with certain Company products (collectively, &#8220;<span style="text-decoration: underline">Pharmaceutical Services</span>&#8221;)
in jurisdictions other than the United States, including, without limitation, Mexico and the United Kingdom, where Epiq Scripts does
not currently maintain licenses or permits (&#8220;<span style="text-decoration: underline">Future Jurisdictions</span>&#8221;, which shall also include, to the extent applicable,
any state in the United States in which Epiq Scripts does not then hold required permits or licenses for the provision of the Pharmaceutical
Services) and/or to terminate Epiq Scripts&#8217; rights to provide exclusive Pharmaceutical Services in any current state of the United
States or Future Jurisdiction where Epiq Scripts may then be providing Pharmaceutical Services to the Company (each a &#8220;<span style="text-decoration: underline">Current
Jurisdiction</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically,
the parties agreed in the First Amendment that should the Company decide to transfer any services provided by Epiq Scripts in a Current
Jurisdiction to another pharmaceutical service provider (&#8220;<span style="text-decoration: underline">Transferred Services</span>&#8221;), the Company will be required to
pay Epiq Scripts a fee of 1% of the total gross sales of all Prescription Products (defined below) by the Company resulting from the
Transferred Services in the Current Jurisdiction, for a period of the lesser of (a) five (5) years from the date the Company transferred
the Transferred Services; and (b) through the end of the term of the MSA (including where applicable, any renewal term)(the &#8220;<span style="text-decoration: underline">Non-Use
Fee</span>&#8221;). The Non-Use Fee is payable monthly in arrears, for calendar quarters, by the 15th day following the end of each calendar
quarter. &#8220;<span style="text-decoration: underline">Prescription Products</span>&#8221; means Products (as defined in the MSA) sold by the Company which must be prescribed
by a medical doctor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the above, the Non-Use Fee shall not apply, and the Company shall not be obligated to pay any Non-Use Fee (a) in the event that the Transferred
Services are provided directly by the Company or a majority-owned subsidiary of the Company; (b) in the event the Company decides to
enter into an agreement with another pharmaceutical service provider to provide Pharmaceutical Services in a Future Jurisdiction; or
(c) in connection with any services provided by any parties in any Future Jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
First Amendment also provides that until the fifth anniversary of the First Amendment, the Company shall notify Epiq Scripts in writing
of any plans to (a) expand its need for pharmacy services outside of those contemplated by the MSA; (b) expand its need for pharmacy
services into a new jurisdiction which Epiq Scripts does not then operate in (including, but not limited to new countries); or (c) begin
providing pharmacy services internally (either through organic growth or acquisition). Thereafter Epiq Scripts has the right to provide
the Company written notice of its intention to provide such services (as described in (a) or (b) above, whereafter the Company is required
to discuss and negotiate such services in good faith with Epiq Scripts for a period of not less than 15 days). Otherwise, in the event
of the occurrence of an event discussed in (c) above, the Company is required to discuss the possibility of Epiq Scripts either co-operating
the pharmacy or providing management services to the Company in good faith for 15 days. In the event after such 15 day period, the Company
and Epiq Scripts cannot come to a mutually agreeable agreement, the Company is under no further obligation regarding the matter set forth
in the notice provided to Epiq Scripts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finally,
the First Amendment includes a requirement whereby if Epiq Scripts receives notice of any proposed fundamental transaction involving
Epiq Scripts or its assets, including any agreement, arrangement, offer or proposal (including a letter of intent, term sheet, form of
definitive agreement or definitive agreement) for an asset sale or acquisition, merger, acquisition or sale of securities, or redemption
or repurchase of securities, Epiq Scripts must provide the Company notice of such offer within three days, after which receipt the Company
will have the right of first refusal for 30 days to become the purchaser in connection with the notified transaction, on the terms, and
subject to the conditions, set forth in such notified offer and pursuant to the conditions of the First Amendment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
* * * *</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copies
of the Consulting Agreement and First Amendment are filed as <span style="text-decoration: underline">Exhibits 10.1</span> and <span style="text-decoration: underline">10.3</span> to this Current Report on Form 8-K
and are incorporated herein by reference. The above description of the terms of the Consulting Agreement and First Amendment is qualified
in its entirety by reference to such exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01. Financial Statements and Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
    of Exhibit</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*&#163;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Consulting Agreement dated September 15, 2023, by and between Mangoceuticals, Inc. and Epiq Scripts, LLC</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2&#163;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-4.htm" style="-sec-extract: exhibit">Master Services Agreement and Statement of Work dated September 1, 2022, and effective August 31, 2022, between Epiq Scripts, LLC and Mangoceuticals, Inc. (filed as Exhibit 10.4 to the Registration Statement on Form S-1 filed by the Company with the Securities and Exchange Commission on January 13, 2023, and incorporated herein by reference)(File Number: 333-269240)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-3.htm">First Addendum to Master Services Agreement dated September 15, 2023, by and between Mangoceuticals, Inc. and Epiq Scripts, LLC</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL for the cover page of this Current Report on Form 8-K</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#163;
Certain portions of these Exhibits have been omitted in accordance with Regulation S-K Item 601 because they are both (i) not material
to investors and (ii) the type of information that the Registrant customarily and actually treats as private or confidential, and have
been marked with &#8220;[***]&#8221; to indicate where omissions have been made. The Registrant agrees to furnish supplementally an unredacted
copy of the Exhibit to the SEC upon its request.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANGOCEUTICALS,
    INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    September 21, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>By:</i></span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Jacob D. Cohen &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob
    D. Cohen</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwjAQhU/QOwxZi6apLuzSoiJWkSLiNtipBNtMmaT+HMlbGlvEYWAY3vveE2Ik1rQyNTKcF0UOR2zaWnuEAitktBcMjmyzTSHcAq/GedbW9+8PzCgwGJjZWEkdhN56Nw7LFOR8ouKJSkDG6TSBw05EXz0jW5kSrTe6Bm1LODC1bNBrfg0JR/0kS82rrzohO0M2hXgsB/kNSsYK9nTXD+KbgzzPRDTqJxJrpq791nTOUwPLGpvQ5Qb0v9EHFn9JRw== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<DESCRIPTION>EPIQ SCRIPTS CONSULTING AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH &ldquo;[***]&rdquo;. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED
FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE
OR CONFIDENTIAL.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSULTING
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
CONSULTING AGREEMENT</B> (this &ldquo;<B><U>Agreement</U></B>&rdquo;) is made this 15<SUP>th</SUP> day of September 2023 (the &ldquo;<B><U>Effective
Date</U></B>&rdquo;), by and between Mangoceuticals, Inc., a Texas corporation (the &ldquo;<B><U>Company</U></B>&rdquo;), and Epiq Scripts,
LLC, a Texas limited liability company (the &ldquo;<B><U>Consultant</U></B>&rdquo;) (each of the Company and Consultant is referred to
herein as a &ldquo;<B><U>Party</U></B>&rdquo;, and collectively referred to herein as the &ldquo;<B><U>Parties</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>W
I T N E S S E T H:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Company desires to obtain the services of Consultant, and Consultant desires to provide consulting services to the Company upon the
terms and conditions hereinafter set forth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, in consideration of the premises, the agreements herein contained and other good and valuable consideration, receipt and
sufficiency of which is hereby acknowledged, the Parties hereto agree as of the Effective Date as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENGAGEMENT;
TERM; SERVICES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.
<U>Services</U>. Pursuant to the terms and conditions hereinafter set forth, the Company hereby engages Consultant, and Consultant hereby
accepts such engagement, to provide pharmacy consulting services in connection with the Company&rsquo;s global expansion efforts, and
as reasonably requested by the Company during the Term of this Agreement (the &ldquo;<B><U>Services</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.
<U>Term</U>. Consultant shall begin providing Services hereunder on the date of this Agreement above (the &ldquo;<B><U>Effective Date</U></B>&rdquo;),
and this Agreement shall remain in effect until the earlier of (a) five (5) years, or (b) terminated as provided in ARTICLE III, below
(the &ldquo;<B><U>Term</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3.
<U>Allocation of Time and Energies</U>. The Consultant hereby promises to perform and discharge faithfully the Services which may be
requested from the Consultant from time to time by the Company and duly authorized representatives of the Company. The Consultant shall
provide the Services required hereunder in a diligent and professional manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 11</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSIDERATION;
EXPENSES; INDEPENDENT CONTRACTOR; TAXES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.
<U>Consideration</U>. During the Term of this Agreement, for all Services rendered by Consultant hereunder and all covenants and conditions
undertaken by the Parties pursuant to this Agreement, the Company shall pay, and Consultant shall accept, as compensation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.1
A one-time payment of $65,000, payable within ten (10) days of the Effective Date (the &ldquo;<B><U>Initial Payment</U></B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.2
Consideration based on the number of Prescription Pills Sold, as follows, provided that no such consideration shall be due until the
First Sale (defined below):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
[***] for every Prescription Pill Sold (each as defined below) by the Company throughout the Territory for cash consideration, after
the First Sale, during the period from the Effective Date until the 1st anniversary of the Effective Date (the &ldquo;<B><U>Year 1 Payments</U></B>&rdquo;),
if any;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
[***] for every Prescription Pill Sold by the Company throughout the Territory for cash consideration, after the First Sale, during the
period from the 1st anniversary of the Effective Date until the 2nd anniversary of the Effective Date (the &ldquo;<B><U>Year 2 Payments</U></B>&rdquo;),
if any;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
[***] for every Prescription Pill Sold by the Company throughout the Territory for cash consideration, after the First Sale, during the
period from the 2nd anniversary of the Effective Date until the 3rd anniversary of the Effective Date (the &ldquo;<B><U>Year 3 Payments</U></B>&rdquo;),
if any;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
[***] for every Prescription Pill Sold by the Company throughout the Territory for cash consideration, after the First Sale, during the
period from the 3rd anniversary of the Effective Date until the 4th anniversary of the Effective Date (the &ldquo;<B><U>Year 4 Payments</U></B>&rdquo;),
if any; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
[***] for every Prescription Pill Sold by the Company throughout the Territory for cash consideration, after the First Sale, during the
period from the 4th anniversary of the Effective Date until the 5th anniversary of the Effective Date, if any (the &ldquo;<B><U>Year
5 Payments</U></B>&rdquo;, and the Year 5 Payments, together with the Year 1 Payments, Year 2 Payments, Year 3 Payments and Year 4 Payments,
collectively, the &ldquo;<B><U>Sales Payments</U></B>&rdquo;, and the Sales Payments together with the Initial Payment, the &ldquo;<B><U>Consulting
Fees</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Territory</U></B>&rdquo;
means worldwide, except for the United States, including its territories and possessions and the District of Columbia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>First
Sale</U></B>&rdquo; means the date that the first commercial sale of Prescription Pills occurs in the Territory. For the sake of clarity,
no Sales Payments shall be due for the sale of any Prescription Pills until the First Sale, nor shall the Consultant be due any Sales
Payments for Prescription Pills sold prior to the First Sale or in a jurisdiction other than the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Prescription
Pills</U></B>&rdquo; means each prescription drug pill sold by the Company to the extent such pill must be prescribed by a medical doctor,
or sold through retail pharmacies over the counter, in jurisdictions where a doctor&rsquo;s prescription is not required for the sale
of such drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 11</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Sold</U></B>&rdquo;
means that a Prescription Pill is sold for cash, which is actually received by the Company during the applicable period, and does not
include any Prescription Pill for which the Company does not receive cash consideration or which cash consideration is subsequently refunded,
including, but not limited, as a result of returns, rejections, discounts, rebates, chargebacks and other refunds relating to Prescription
Pills, and allowances and adjustments actually credited to customers for Prescription Pills that are spoiled, damaged, outdated, obsolete,
returned or otherwise recalled, but only if and to the extent the same are in accordance with sound business practices and not in excess
of customary industry standards. To the extent that the purchase price of any Prescription Pill which is Sold is subsequently refunded,
charged back, returned, or reimbursed to a purchaser (each a &ldquo;<B><U>Refund</U></B>&rdquo;), the Company shall be able to set off
the amount of any Sales Payments already paid in connection with such Refunded Prescription Pills, against future Sales Payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.
<U>Accounting For, and Payments In Connection with, Sales Payments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1
Beginning on the first calendar month after the Effective Date, and for every subsequent calendar month thereafter during the Term, the
Company will pay the applicable Sales Payments per calendar month for each Prescription Pill Sold in accordance with the above schedule
based on each Prescription Pill Sold for which the Company received cash. Such payments will be payable to Consultant in arrears, on
a calendar quarterly basis during the Term, by each of January 15th, April 15th, July 15th, and October 15th, for each of the quarters
ended December 31st, March 31st, June 30th and September 30th, respectively, beginning on the 15<SUP>th</SUP> calendar day of the calendar
month following the calendar month during which the First Sale occurs, provided that if any of the above payment dates shall fall on
a non-Business Day, such payment shall be due on the next Business Day following such stated payment date. The final payment due hereunder
shall be paid on the Termination Date for the period between the end of the last calendar quarter and the Termination Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.2
In connection with each Sales Payment, the Company shall provide a statement setting forth the calculation of the Sales Payment (the
&ldquo;<B><U>Accountings</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.3
Future Sales Payments shall be offset equitably by the Company for any Prescription Pill Sold which is later Refunded (collectively &ldquo;<B><U>Adjustments</U></B>&rdquo;),
which Adjustments shall be made to the aggregate Sales Payments in the calendar month during which they are incurred by the Company,
and shall be included in the Accountings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.4
All payments by the Company hereunder shall be made in the lawful money of the United States of America in immediately available funds
on the dates specified herein and shall be delivered to Consultant or its designee as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
If via wire transfer, pursuant to wire instructions provided from time to time by Consultant for deposit into an account designated from
time to time by Consultant for Consultant&rsquo;s benefit; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
If via check, to the address or to the attention of such other person as specified by prior written notice to Consultant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.5
Time is of the essence in all obligations of the Company hereunder, including, without limitation, payment of the Sales Payments as expressly
provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 11</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.
<U>Records and Audit Right</U>. The Company agrees that it shall keep accurate and complete records and books of account concerning all
Prescription Pills Sold during the Term of this Agreement and for two years thereafter. All records and documents relating to Prescription
Pills Sold shall be subject to examination, inspection, copying, or audit by personnel authorized by Consultant and/or any third party
auditor or accountant designated by Consultant. Except in the event of a good faith dispute between the Parties, such audits shall occur
no more than once per 12 month period, upon prior written request. The Company shall provide Consultant with the requested documents
or provide adequate and appropriate workspace at the Company&rsquo;s location in order to conduct such audits. During the two (2) year
period after expiration or termination of this Agreement or one (1) year following the completion of any litigation between the Parties,
delivery of and access to these items will be at no cost to Consultant. Any audit under this <U>Section 2.3</U> may only be conducted
during reasonable business hours. If the audit reveals Consultant has been underpaid by more than five percent (5%), the Company will
reimburse Consultant for all costs and expenses incurred in connection with such audit. The Company will promptly pay Consultant any
amounts shown by any such audit to be owing with interest at 10% per annum, from the original date due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.
<U>Independent Contractor</U>. It is the express intention of the Company and Consultant that Consultant perform the Services as an independent
contractor to the Company. Nothing in this Agreement shall in any way be construed to constitute Consultant as an agent or employee of
the Company. Without limiting the generality of the foregoing, Consultant is not authorized to bind the Company to any liability or obligation
or to represent that Consultant has any such authority in connection with the Services. Consultant acknowledges and agrees that Consultant
is obligated to report as income all compensation received by Consultant pursuant to this Agreement. Consultant agrees to and acknowledges
the obligation to pay all self-employment and other taxes on such income. The Company and Consultant agree that Consultant will receive
no Company-sponsored benefits from the Company pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.
<U>Expenses</U>. The Company agrees to reimburse Consultant for its reasonable, documented out-of-pocket expenses associated with the
Services (the &ldquo;<B><U>Expenses</U></B>&rdquo;), subject to the Company&rsquo;s normal and usual reimbursement policies of its employees
and consultants, provided that the Consultant shall receive written authorization of any one-time Expense greater than $500 not included
in a pre-approved budget relating to the Services. Additionally, in the event that any employees of the Consultant are required to travel
more than 50 miles in order to perform the Services, the Company will pay the Consultant, upon prior written approval thereof, a per
diem of $1,000 per day, in addition to the reimbursement of Expenses, subject to the above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.
<U>Taxes</U>. The Company makes no representations or warranties with respect to the tax consequences of the payments and any other consideration
provided to Consultant under the terms of this Agreement. Consultant agrees and understands that it is responsible for payment, if any,
of local, state, and/or federal taxes on the payments and any other consideration provided hereunder by the Company and any penalties
or assessments thereon. Consultant agrees to indemnify and hold harmless the Company and its affiliates and their directors, officers
and employees from and against all taxes, losses, damages, liabilities, costs and expenses, including attorneys&rsquo; fees and other
legal expenses, arising solely from or in connection with (i) any obligation imposed on the Company to pay withholding taxes or similar
items, or (ii) any determination by a court or agency that the Consultant is not an independent contractor pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 11</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TERMINATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.
<U>Termination</U>. The obligations under this Agreement shall begin on the Effective Date and continue to bind the Parties until the
earlier of the (a) the expiration of the Term; (b) the date this Agreement is mutually terminated by the Parties; (c) the date this Agreement
is terminated by the Company due to the breach by the Consultant of any term or condition of this Agreement, which breach is not cured
within thirty (30) days of written notice thereof by the Company to the Consultant; and (d) the date the Consultant issues a written
termination notice to the Company, which may be issued at any time, for any reason or no reason.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.
<U>Termination Date</U>. &ldquo;<B><U>Termination Date</U></B>&rdquo; shall mean the date on which Consultant&rsquo;s engagement with
the Company hereunder is actually terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.
<U>Rights Upon Termination</U>. Upon termination of the Term, the Consultant shall be paid any and all Consulting Fees accrued and due
through the Termination Date, which shall represent the sole compensation and fees due to Consultant. The Consultant shall also continue
to comply with the terms of ARTICLE IV hereof following the Termination Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONFIDENTIAL/TRADE
SECRET INFORMATION;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY
PROPERTY; NON-SOLICITATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.
<U>Confidential/Trade Secret Information/Non-Disclosure/Non-Solicitation</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.1
<U>Confidential/Trade Secret Information Defined</U>. During the course of Consultant&rsquo;s engagement, Consultant will have access
to various Confidential/Trade Secret Information of the Company and information developed for the Company. For purposes of this Agreement,
the term &ldquo;<B><U>Confidential/Trade Secret Information</U></B>&rdquo; is information that is not generally known to the public and,
as a result, is of economic benefit to the Company in the conduct of its business, and the business of the Company&rsquo;s subsidiaries.
Consultant and the Company agree that the term &ldquo;<B><U>Confidential/Trade Secret Information</U></B>&rdquo; includes but is not
limited to all information developed or obtained by the Company, including its affiliates, and predecessors, and comprising the following
items, whether or not such items have been reduced to tangible form (e.g., physical writing, computer hard drive, disk, tape, etc.):
all methods, techniques, processes, ideas, research and development, product designs, engineering designs, plans, models, production
plans, business plans, add-on features, trade names, service marks, slogans, forms, pricing structures, business forms, marketing programs
and plans, layouts and designs, financial structures, operational methods and tactics, cost information, the identity of and/or contractual
arrangements with suppliers and/or vendors, accounting procedures, and any document, record or other information of the Company relating
to the above. Confidential/Trade Secret Information includes not only information directly belonging to the Company which existed before
the date of this Agreement, but also information developed by Consultant for the Company, including its subsidiaries, affiliates and
predecessors, during the term of Consultant&rsquo;s engagement with the Company. Confidential/Trade Secret Information does not include
any information which (a) was in the lawful and unrestricted possession of Consultant prior to its disclosure to Consultant by the Company,
its subsidiaries, affiliates or predecessors, or owned thereby, which shall be included in Confidential/Trade Secret Information, (b)
is or becomes generally available to the public by lawful acts other than those of Consultant after receiving it, or (c) has been received
lawfully and in good faith by Consultant from a third party who is not and has never been a Consultant of the Company, its subsidiaries,
affiliates or predecessors, and who did not derive it from the Company, its subsidiaries, affiliates or predecessors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 11</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.2
<U>Restriction on Use of Confidential/Trade Secret Information</U>. Consultant agrees that during the Term and the two-year period following
the Termination Date, its use of Confidential/Trade Secret Information is subject to the following restrictions so long as the Confidential/Trade
Secret Information has not become generally known to the public:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Non-Disclosure</U>. Consultant agrees that it will not publish or disclose, or allow to be published or disclosed, Confidential/Trade
Secret Information to any person without the prior written authorization of the Company unless pursuant to or in connection with Consultant&rsquo;s
job duties to the Company under this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Non-Removal/Surrender</U>. Consultant agrees that it will not remove any Confidential/Trade Secret Information from the offices of
the Company or the premises of any facility in which the Consultant is performing services for the Company, except pursuant to its duties
under this Agreement. Consultant further agrees that it shall surrender to the Company all documents and materials in its possession
or control which contain Confidential/Trade Secret Information and which are the property of the Company upon the termination of its
engagement with the Company, and that it shall not thereafter retain any copies of any such materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.
<U>Non-Solicitation of Employees and Consultants</U>. Consultant agrees that during the Term and the twelve-month period following the
Termination Date, it shall not, directly or indirectly, solicit or otherwise encourage any employees or consultants of the Company to
leave the employ or service of the Company, or solicit, directly or indirectly, any of the Company&rsquo;s employees or consultants for
employment or service; provided, however, that Consultant may solicit an employee or consultant if (i) such employee or consultant has
resigned voluntarily (without any solicitation from Consultant), and at least one (1) year has elapsed since such employee&rsquo;s or
consultant&rsquo;s resignation from employment or termination of service with the Company, (ii) such employee&rsquo;s employment or consultant&rsquo;s
services was terminated by the Company, and if one (1) year has elapsed since such employee or consultant was terminated by the Company,
(iii) the Company has consented to the solicitation of such employee or consultant in writing, which consent the Company may withhold
in its sole discretion, or (iv) such solicitation solely occurs by general solicitations for employment to the public.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.
<U>Non-Solicitation of Contacts</U>. Consultant agrees that during the Term and the twelve-month period following the Termination Date,
Consultant shall not: (a) interfere with the Company&rsquo;s business relationship with its customers or suppliers, (b) solicit, directly
or indirectly, or otherwise encourage any of the Company&rsquo;s customers or suppliers to terminate their business relationship with
the Company, or (c) solicit, directly or indirectly, or otherwise encourage any employees of the Company to leave the employ of the Company,
or solicit any of the Company&rsquo;s employees for employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 11</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.
<U>Breach of Provisions</U>. If Consultant materially breaches any of the provisions of this ARTICLE IV, or in the event that any such
breach is threatened by Consultant, in addition to and without limiting or waiving any other remedies available to the Company at law
or in equity, the Company shall be entitled to immediate injunctive relief in any court, domestic or foreign, having the capacity to
grant such relief, to restrain any such breach or threatened breach and to enforce the provisions of this ARTICLE IV.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5.
<U>Reasonable Restrictions</U>. The Parties acknowledge that the foregoing restrictions, as well as the duration and the territorial
scope thereof as set forth in this ARTICLE IV, are under all of the circumstances reasonable and necessary for the protection of the
Company and its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6.
<U>Specific Performance</U>. Consultant acknowledges and agrees that the Company&rsquo;s remedies at law for a breach or threatened breach
of any of the provisions of ARTICLE IV would be inadequate and, in recognition of this fact, Consultant agrees that, in the event of
such a breach or threatened breach, in addition to any remedies at law, the Company, without posting any bond, shall be entitled to obtain
equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction or any other equitable
remedy which may then be available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7.
<U>Company Property</U>. Upon termination of this Agreement, or on demand by the Company during the Term of this Agreement, Consultant
will immediately deliver to the Company, and will not keep in its possession, recreate or deliver to anyone else, any and all Company
property, records, data, notes, notebooks, reports, files, proposals, lists, correspondence, specifications, drawings blueprints, sketches,
materials, photographs, charts, all documents and property, and reproductions of any of the aforementioned items that were developed
by Consultant pursuant to the terms of this Agreement, obtained by Consultant in connection with the provision of the Services, or otherwise
belonging to the Company or its successors or assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MUTUAL
REPRESENTATIONS, COVENANTS AND</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WARRANTIES
OF THE PARTIES; LIMITATION OF LIABILITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.
<U>Power and Authority</U>. The Parties have all requisite power and authority, corporate or otherwise, to execute and deliver this Agreement
and to consummate the transactions contemplated hereby and thereby. The Parties have duly and validly executed and delivered this Agreement
and will, on or prior to the consummation of the transactions contemplated herein, execute, such other documents as may be required hereunder
and, assuming the due authorization, execution and delivery of this Agreement by the Parties hereto and thereto, this Agreement constitutes,
the legal, valid and binding obligation of the Parties enforceable against each Party in accordance with its terms, except as such enforcement
may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the Parties rights generally
and general equitable principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 11</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.
<U>Execution and Delivery</U>. The execution and delivery by the Parties of this Agreement and the consummation of the transactions contemplated
hereby and thereby do not and shall not, by the lapse of time, the giving of notice or otherwise: (a) constitute a violation of any law;
or (b) constitute a breach or violation of any provision contained in the Certificate of Formation, Bylaws or Operating Agreement, or
such other document(s) regarding organization and/or management of the Parties, if applicable; or (c) constitute a breach of any provision
contained in, or a default under, any governmental approval, any writ, injunction, order, judgment or decree of any governmental authority
or any contract to which the Parties are bound or affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.
<U>Authority of Entities</U>. Any individual executing this Agreement on behalf of an entity has authority to act on behalf of such entity
and has been duly and properly authorized to sign this Agreement on behalf of such entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4.
In no event will either Party be liable to the other Party for any claim or cause of action requesting or claiming any incidental, consequential,
special, indirect, statutory, punitive or reliance damages. Any claim or cause of action requesting or claiming such damages is specifically
waived and barred, whether such damages were foreseeable or not or a Party was notified in advance of the possibility of such damages.
Damages prohibited under this Agreement will include, without limitation, damage or loss of property or equipment, loss of profits, revenues
or savings, cost of capital, cost of replacement services, opportunity costs and cover damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
VI.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MISCELLANEOUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.
<U>Notices</U>. All notices, approvals, consents, requests, and other communications hereunder shall be in writing and shall be delivered
(i) by personal delivery, or (ii) by national overnight courier service, or (iii) by certified or registered mail, return receipt requested,
or (iv) via facsimile transmission, with confirmed receipt, or (v) via email. Notice shall be effective upon receipt except for notice
via fax (as discussed above) or email, which shall be effective only when the recipient, by return or reply email or notice delivered
by other method provided for in this <U>Section 6.1</U>, acknowledges having received that email (with an automatic &ldquo;<B><U>read
receipt</U></B>&rdquo; or similar notice not constituting an acknowledgement of an email receipt for purposes of this <U>Section 6.1</U>,
or which such recipient &lsquo;replies&rsquo; to such prior email). Such notices shall be sent to the applicable party or parties at
the address specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>If
    to the Company</U>:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals,
    Inc.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Jacob Cohen</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15110
    Dallas Parkway, Suite 600</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dallas,
    Texas 75248</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    <U>jacob@mangorx.com</U></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>If
    to the Consultant:</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Epiq
    Scripts, LLC</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Sultan Haroon</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">465
    W. President George Bush Hwy, Suite 240</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richardson,
    Texas 75080</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    sultan@epiqscripts.com</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 11</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2.
<U>Binding Effect; Assignment</U>. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective
legal representatives, heirs, successors and assigns. Consultant may not assign any of its rights or obligations under this Agreement.
The Company may assign its rights and obligations under this Agreement to any successor entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.
<U>Severability</U>. If any provision of this Agreement, or portion thereof, shall be held invalid or unenforceable by a court of competent
jurisdiction, such invalidity or unenforceability shall attach only to such provision or portion thereof, and shall not in any manner
affect or render invalid or unenforceable any other provision of this Agreement or portion thereof, and this Agreement shall be carried
out as if any such invalid or unenforceable provision or portion thereof were not contained herein. In addition, any such invalid or
unenforceable provision or portion thereof shall be deemed, without further action on the part of the Parties hereto, modified, amended
or limited to the extent necessary to render the same valid and enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.
<U>Waiver</U>. No waiver by a Party of a breach or default hereunder by the other Party shall be considered valid, unless expressed in
a writing signed by such first Party, and no such waiver shall be deemed a waiver of any subsequent breach or default of the same or
any other nature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5.
<U>Entire Agreement</U>. This Agreement sets forth the entire agreement between the Parties with respect to the subject matter hereof,
and supersedes any and all prior agreements between the Company and Consultant, whether written or oral, relating to any or all matters
covered by and contained or otherwise dealt with in this Agreement. This Agreement does not constitute a commitment of the Company with
regard to Consultant&rsquo;s engagement, express or implied, other than to the extent expressly provided for herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6.
<U>Amendment</U>. No modification, change or amendment of this Agreement or any of its provisions shall be valid, unless in a writing
signed by the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7.
<U>Captions</U>. The captions, headings and titles of the sections of this Agreement are inserted merely for convenience and ease of
reference and shall not affect or modify the meaning of any of the terms, covenants or conditions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8.
<U>Governing Law</U>. This Agreement, and all claims or causes of action (whether in contract, tort or statute) that may be based upon,
arise out of or relate to this Agreement, or the negotiation, execution or performance of this Agreement (including any claim or cause
of action based upon, arising out of or related to any representation or warranty made in or in connection with this Agreement or as
an inducement to enter into this Agreement), shall be governed by, and enforced in accordance with, the internal laws of the State of
Texas, including its statutes of limitations, without regard to any borrowing statute that would result in the application of the statute
of limitations of any other jurisdiction. Any actions and proceedings arising out of or relating directly or indirectly to this Agreement
or any ancillary agreement or any other related obligations shall be litigated solely and exclusively in the state or federal courts
located in Dallas County, Texas, and those such courts are convenient forums. Each Party hereby submits to the personal jurisdiction
of such courts for purposes of any such actions or proceedings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 11</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9.
<U>Survival</U>. The termination of Consultant&rsquo;s engagement with the Company pursuant to the provisions of this Agreement shall
not affect Consultant&rsquo;s obligations to the Company hereunder which by the nature thereof are intended to survive any such termination,
including, without limitation, Consultant&rsquo;s obligations under ARTICLE IV of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.10.
<U>No Presumption from Drafting</U>. This Agreement has been negotiated at arm&rsquo;s-length between persons knowledgeable in the matters
set forth within this Agreement. Accordingly, given that all Parties have had the opportunity to draft, review and/or edit the language
of this Agreement, no presumption for or against any Party arising out of drafting all or any part of this Agreement will be applied
in any action relating to, connected with or involving this Agreement. In particular, any rule of law, legal decisions, or common law
principles of similar effect that would require interpretation of any ambiguities in this Agreement against the Party that has drafted
it, is of no application and is hereby expressly waived. The provisions of this Agreement shall be interpreted in a reasonable manner
to affect the intentions of the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.11.
<U>Review and Construction of Documents</U>. Each Party herein expressly represents and warrants to all other Parties hereto that (a)
before executing this Agreement, said Party has fully informed itself of the terms, contents, conditions and effects of this Agreement;
(b) said Party has relied solely and completely upon its own judgment in executing this Agreement; (c) said Party has had the opportunity
to seek and has obtained the advice of its own legal, tax and business advisors before executing this Agreement; (d) said Party has acted
voluntarily and of its own free will in executing this Agreement; and (e) this Agreement is the result of arm&rsquo;s length negotiations
conducted by and among the Parties and their respective counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.12.
<U>Interpretation</U>. When used in this Agreement, unless a contrary intention appears: (i) a term has the meaning assigned to it; (ii)
&ldquo;<B><U>or</U></B>&rdquo; is not exclusive; (iii) &ldquo;<B><U>including</U></B>&rdquo; means including without limitation; (iv)
words used herein regardless of the number and gender specifically used, shall be deemed and construed to include any other number, singular
or plural, and any other gender, masculine, feminine or neuter, as the context requires; (v) any agreement, instrument or statute defined
or referred to herein or in any instrument or certificate delivered in connection herewith means such agreement, instrument or statute
as from time to time amended, modified or supplemented and includes (in the case of agreements or instruments) references to all attachments
thereto and instruments incorporated therein; (vi) the words &ldquo;<B><U>hereof</U></B>&rdquo;, &ldquo;<B><U>herein</U></B>&rdquo; and
&ldquo;<B><U>hereunder</U></B>&rdquo; and words of similar import when used in this Agreement shall refer to this Agreement as a whole
and not to any particular provision hereof; (vii) references contained herein to Article, Section, Schedule and Exhibit, as applicable,
are references to Articles, Sections, Schedules and Exhibits in this Agreement unless otherwise specified; and (viii) references to &ldquo;<B><U>writing</U></B>&rdquo;
include printing, typing, lithography and other means of reproducing words in a visible form, including, but not limited to email.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.13.
<U>Electronic Signatures and Counterparts</U>. This Agreement and any signed agreement or instrument entered into in connection with
this Agreement, and any amendments hereto or thereto, may be executed in one or more counterparts, all of which shall constitute one
and the same instrument. Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .jpeg
or similar attachment to electronic mail (any such delivery, an &ldquo;<B><U>Electronic Delivery</U></B>&rdquo;) shall be treated in
all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were
the original signed version thereof delivered in person. At the request of any Party, each other Party shall re execute the original
form of this Agreement and deliver such form to all other Parties. No Party shall raise the use of Electronic Delivery to deliver a signature
or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a
defense to the formation of a contract, and each such Party forever waives any such defense, except to the extent such defense relates
to lack of authenticity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> of 11</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the Parties hereto have executed this Agreement as of the day and year first above written, to be effective as of
the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&ldquo;<B><U>COMPANY</U></B>&rdquo;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Mangoceuticals, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Jonathan Arango</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">Its:</TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt"> President</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Printed Name: Jonathan Arango</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&ldquo;<B><U>CONSULTANT</U></B>&rdquo;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Epiq Scripts, LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Sultan Haroon</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Its:</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">Director</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Printed Name: Sultan Haroon</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> of 11</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>ex10-3.htm
<DESCRIPTION>1ST AMENDMENT TO MSA WITH EPIQ SCRIPTS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FIRST
ADDENDUM TO MASTER SERVICES AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
FIRST ADDENDUM TO MASTER SERVICES AGREEMENT</B> (this &ldquo;<B><U>Addendum</U></B>&rdquo;), entered into and effective as of September
15, 2023 (the &ldquo;<B><U>Effective Date</U></B>&rdquo;), will act to modify, amend and serve as an addendum to, that certain Master
Services Agreement (as amended from time to time, the &ldquo;<B><U>Agreement</U></B>&rdquo;) dated September 1, 2022 between Epiq Scripts,
LLC (&ldquo;<B><U>Epiq Scripts</U></B>&rdquo;), and Mangoceuticals, Inc. (&ldquo;<B><U>Customer</U></B>&rdquo;), each a &ldquo;<B><U>Party</U></B>&rdquo;
and collectively the &ldquo;<B><U>Parties</U></B>&rdquo;. Unless expressly defined herein, all defined terms referenced herein shall
have the same definitions as set forth in the Agreement. If any term in the Agreement conflicts with any provision of this Addendum,
the provision of this Addendum shall take precedence and govern, and any such term shall be of no effect whatsoever to the extent applied
to the subject matter of this Addendum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
Epiq Scripts and Customer entered into the Agreement, for Epiq Scripts, as Customer&rsquo;s exclusive provider, to provide certain pharmacy
and related services (defined as Services in the Agreement) to Customer in the United States;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
Epiq Scripts agrees to provide Customer with all compounding records in association with all Mango CPI and any future Mango CPI (as defined
below);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Parties also desire to amend the Agreement to include certain Right of First Negotiation Rights and Right of First Refusal Rights,
as well as certain exclusivity rights, on the terms and subject to the conditions set forth below;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Agreement provides for Epiq Scripts to be the Customer&rsquo;s exclusive provider of Services during the Term of the Agreement as
long as Epiq Scripts complies with the terms of the Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS,
</B>Customer desires to expand its operations beyond the United States to other countries, including, without limitation, Mexico and
the United Kingdom, where Epiq Scripts does not currently maintain licenses or permits (&ldquo;<B><U>Future Jurisdictions</U></B>&rdquo;,
which shall also include, to the extent applicable, any state in the United States in which Epiq Scripts does not then hold required
permits or licenses for the provision of the Pharmaceutical Services (as defined below)); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
Epiq Scripts and Customer desire to enter into this Addendum to provide for certain rights to Epiq Scripts in the event that the Customer
seeks to obtain Services or pharmaceutical services in connection with the Products (collectively, &ldquo;<B><U>Pharmaceutical Services</U></B>&rdquo;)
in a Future Jurisdiction and/or to terminate Epiq Scripts&rsquo; rights to provide exclusive Services in any current state of the United
States or Future Jurisdiction where Epiq Scripts may then be providing Services to Customer (each a &ldquo;<B><U>Current Jurisdiction</U></B>&rdquo;),
as set forth in greater detail below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIQ SCRIPTS, LLC &ndash; MANGOCEUTICALS, INC.</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST ADDENDUM TO MASTER SERVICES AGREEMENT - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW
THEREFORE</B>, in recognition of the above Recitals and in consideration of the agreements, mutual covenants, terms and conditions set
forth in the Agreement and this Addendum, and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged and confirmed, the Parties hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
I.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFINITIONS.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise required by the context in which a defined term appears, or otherwise set forth, the following terms shall have the meanings
specified in this <U>ARTICLE I</U>. Terms that are defined in other Articles shall have the meanings given to them in those Articles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.
&ldquo;<B><U>Affiliate</U></B>&rdquo; means with respect to a specified Person, any Person that directly, or indirectly through one or
more intermediaries, controls, or is controlled by, or is under common control with, the Person specified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.
&ldquo;<B><U>Asset Sale</U></B>&rdquo; means any sale, exchange, assignment, conveyance, transfer, delivery, license, liquidation or
other disposition of any of Epiq Scripts&rsquo; or any of its subsidiaries&rsquo; properties or assets, including Epiq Scripts&rsquo;
or any of its subsidiaries&rsquo; executory contracts and associated resources, other than in the ordinary course of business consistent
with Epiq Scripts&rsquo; and its subsidiaries&rsquo; historic past practice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3.
&ldquo;<B><U>Beneficial Owner</U></B>&rdquo; has the meaning ascribed to it in Rules 13d-3 and 13d-5 under the Securities Exchange Act
of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4.
&ldquo;<B><U>Business Day</U></B>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the
United States or any day on which banking institutions in the State of Texas are authorized or required by law or other governmental
action to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5.
&ldquo;<B><U>Extraordinary Transaction</U></B>&rdquo; means any of the following: <U>(i)</U> any merger, reorganization, share exchange,
consolidation or other business combination involving Epiq Scripts or any of its subsidiaries, other than (A) a merger or consolidation
of Epiq Scripts in which the holders of capital stock or membership interests of Epiq Scripts immediately prior to such merger or consolidation
continue to hold a majority of the capital stock or membership interests of Epiq Scripts or the surviving entity after giving effect
to such merger or consolidation, and (B) any merger or similar transaction effected solely to change the domicile of Epiq Scripts or
any of its subsidiaries; <U>(ii)</U> any acquisition by any Person or Group (including any &ldquo;<B><U>person</U></B>&rdquo; within
the meaning of Section 13(d) of the Securities Exchange Act of 1934, as amended) as a result of which, such Person (or any Group of which
such Person is a member) or Group becomes a Beneficial Owner of 20% or more of the issued and outstanding shares of capital stock or
membership interests of Epiq Scripts or any of its subsidiaries in any single transaction or a series of related transactions; <U>(iii)
</U>any sale, liquidation or transfer of all or substantially all of the assets of Epiq Scripts; or <U>(iv) </U>the redemption or repurchase
of shares or membership interests of Epiq Scripts, the effect of which is that any Person or Group that did not beneficially own a majority
of the voting power of the outstanding shares of capital stock or membership interests of Epiq Scripts immediately prior to such redemption
or repurchase owns at least a majority of such voting power of the outstanding shares of capital stock or membership interests of Epiq
Scripts after such redemption or repurchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6.
&ldquo;<B><U>Future Improvements</U></B>&rdquo; means all Mango CPI known to, created by, obtained by, or invented by, Epiq Scripts after
the Effective Date and relating to (a) the Mango CPI; or (b) any other product(s) sold by Customer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIQ SCRIPTS, LLC &ndash; MANGOCEUTICALS, INC.</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST ADDENDUM TO MASTER SERVICES AGREEMENT - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7.
&ldquo;<B><U>Gross Sales</U></B>&rdquo; means an amount (not less than zero) determined as of the end of any applicable period of determination,
for any applicable period of determination, equal to <B><U>(a)</U></B> the sum of any cash revenues actually received by the Customer
in connection with the sale of Prescription Products for such applicable period of determination, minus <B><U>(b)</U></B>(x) the amount
of any returns, rejections, discounts, rebates, chargebacks and other refunds relating to Prescription Products, and allowances and adjustments
actually credited to customers for Prescription Products that are spoiled, damaged, outdated, obsolete, returned or otherwise recalled,
but only if and to the extent the same are in accordance with sound business practices and not in excess of customary industry standards,
each during the applicable period, or for any other period during which the Non-Use Fee has previously been paid, if affected during
the current period, and each in the case of (a) or (b), as determined in accordance with Generally Accepted Accounting Principles (GAAP)
consistently applied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8.
&ldquo;<B><U>Group</U></B>&rdquo; means two or more Persons acting as a partnership, limited partnership, syndicate or other group for
the purpose of acquiring, holding or disposing of the applicable securities referred to herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9.
&ldquo;<B><U>Mango CPI</U></B>&rdquo; means all production methods, processes, formulations, technology, documents, technical information
concerning equipment, services, processes, technologies and methods, compounding training methods or records and training processes created
by, invented or known to Epiq Scripts relating to the Products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.10.
&ldquo;<B><U>Person</U></B>&rdquo; means any natural person, corporation, limited liability company, general partnership, limited partnership,
trust, proprietorship, joint venture, business organization or government, political subdivision, agency or instrumentality.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.11.
&ldquo;<B><U>Prescription Products</U></B>&rdquo; means Products sold by the Customer which must be prescribed by a medical doctor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.12.
&ldquo;<B><U>Proposal</U></B>&rdquo; means any agreement, arrangement, offer or proposal (including a letter of intent, term sheet, form
of definitive agreement or definitive agreement) for a Sale Event; provided, however, that the term Proposal shall not include any Proposal
by Customer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.13.
&ldquo;<B><U>Representatives</U></B>&rdquo; means, with respect to a Person, such Person&rsquo;s legal, financial, internal and independent
accounting and other advisors and representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.14.
&ldquo;<B><U>Right of First Negotiation Rights</U></B>&rdquo; means those rights of Epiq Scripts set forth in ARTICLE V hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.15.
&ldquo;<B><U>ROFR Term</U></B>&rdquo; means the period from the Effective Date until the fifth (5<SUP>th</SUP>) anniversary of the Effective
Date, unless mutually agreed by the Parties in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.16.
&ldquo;<B><U>Sale Event</U></B>&rdquo; means any Asset Sale or Extraordinary Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIQ SCRIPTS, LLC &ndash; MANGOCEUTICALS, INC.</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST ADDENDUM TO MASTER SERVICES AGREEMENT - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
II.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TERMINATION
OF EXCLUSIVITY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AS
TO FUTURE JURISDICTIONS OR CURRENT JURISDICTIONS.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.
The Parties agree that should Customer decide to transfer any Services provided by Epiq Scripts in a Current Jurisdiction to another
pharmaceutical service provider (&ldquo;<B><U>Transferred Services</U></B>&rdquo;), the Customer shall pay Epiq Scripts a fee of One
Percent (1%) of the total Gross Sales of all Prescription Products (defined below) by Customer resulting from the Transferred Services
in the Current Jurisdiction, for a period of the lesser of (a) five (5) years from the date Customer transferred the Transferred Services;
and (b) through the end of the Term of the Agreement (including where applicable, any Renewal Term)(the &ldquo;<B><U>Non-Use Fee</U></B>&rdquo;).
The Non-Use Fee shall be payable monthly in arrears, for calendar quarters, by the 15<SUP>th</SUP> day following the end of each calendar
quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.
The Parties confirm and acknowledge that the Non-Use Fee shall not apply, and Customer shall not be obligated to pay any Non-Use Fee
(a) in the event that the Transferred Services are provided directly by Customer or a majority-owned subsidiary of Customer; (b) in the
event the Customer decides to enter into an agreement with another pharmaceutical service provider to provide Pharmaceutical Services
in a Future Jurisdiction (&ldquo;<B><U>New Services</U></B>&rdquo;); or (c) in connection with any services provided by any parties in
any Future Jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
III.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RIGHT
OF FIRST NEGOTIATION FOR FUTURE PHARMACY SERVICES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.
During the ROFR Term, Customer agrees to notify Epiq Scripts in writing of any plans to (a) expand its need for pharmacy services outside
of those contemplated by the Agreement; (b) expand its need for pharmacy services into a new jurisdiction which Epiq Scripts does not
then operate in (including, but not limited to new countries); or (c) begin providing pharmacy services internally (either through organic
growth or acquisition) (the &ldquo;<B><U>Customer Notice</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.
Upon receipt of such Customer Notice, Epiq Scripts shall have a period of thirty (30) days to determine whether (i) in connection with
<U>Section 5.1(a)</U> Epiq Scripts desires to seek to expand its operations to meet the demand contemplated by Customer Notice; or (ii)
in connection with <U>Section 5.1(b)</U> Epiq Scripts desires to seek to expand its operations into the new jurisdiction described in
the Customer Notice, and in the case of an affirmative determination pursuant to (i) or (ii), Epiq Scripts shall notify Customer of its
intention and the contemplated timing of such actions (a &ldquo;<B><U>Customer Notice Response</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.
In the event that Epiq Scripts has provided Customer a Customer Notice Response, Customer shall discuss and negotiate the Customer Notice
Response in good faith with Epiq Scripts for a period of not less than fifteen (15) days. In the event the Parties are unable to come
to mutually agreeable terms on Epiq Scripts&rsquo; provision of future services to Customer as contemplated by Customer Notice, after
such fifteen (15) day negotiation period, for any reason, Customer shall be under no further obligation under this ARTICLE V in regards
to such matter descried in Customer Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIQ SCRIPTS, LLC &ndash; MANGOCEUTICALS, INC.</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST ADDENDUM TO MASTER SERVICES AGREEMENT - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.
In the event Customer has provided a Customer Notice pursuant to <U>Section 5.1(c)</U>, Customer shall discuss the Customer Notice in
good faith with Epiq Scripts and the possibility of Epiq Scripts either co-operating the pharmacy or providing management services to
Customer in connection with the event described in the Customer Notice, the fees in connection therewith and services to be provided
in connection therewith, for a period of not less than fifteen (15) days. In the event the Parties are unable to come to mutually agreeable
terms regarding such matters after such fifteen (15) day negotiation period, for any reason, Customer shall be under no further obligation
under this ARTICLE V in regards to such matter described in the applicable Customer Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
IV.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RIGHT
OF FIRST REFUSAL FOR EPIQ SCRIPTS SALE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.
<U>Notice of Proposal</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.1
Within three (3) days of receiving any contemplated Proposal, and prior to agreeing to, entering into, or becoming bound in any way in
connection with, such Proposal, Epiq Scripts shall provide a written notice of such Proposal (the &ldquo;<B><U>Epiq Scripts Notice</U></B>&rdquo;)
to Customer. The Epiq Scripts Notice shall include (i) a true and correct copy of the Proposal, including all schedules, exhibits and
ancillary documents related thereto, and (ii) the expected date of consummation of such transaction contemplated by the Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.2
Immediately after delivering the Epiq Scripts Notice to Customer, Epiq Scripts shall provide Customer and its Representatives access
to, and, if requested, copies of, the information and other diligence materials, including all non-public information of Epiq Scripts
or its subsidiaries, that are or have been supplied to any third party or any third party&rsquo;s Representatives in connection with
the Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.
<U>Right of First Refusal</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.3
<I><U>Right of First Refusal with Respect to an Extraordinary Transaction</U></I>. Upon receipt of Epiq Scripts Notice with respect to
an Extraordinary Transaction, Customer shall have the irrevocable and exclusive option, at its sole discretion, to become, or to have
any of its Affiliates become, the purchaser with respect to the Extraordinary Transaction on substantially the same financial terms as
provided in the Proposal. If Customer elects to become, or to have any of its Affiliates become, the purchaser, Customer shall deliver
a written notice (the &ldquo;<B><U>Customer Proposal Notice</U></B>&rdquo;) to Epiq Scripts of such election within thirty (30) days
from Customer receipt of Epiq Scripts Notice (such thirty (30) day period, the &ldquo;<B><U>Extraordinary Transaction Proposal Review
Period</U></B>&rdquo;). Upon receipt by Epiq Scripts of the Customer Proposal Notice, Epiq Scripts shall not enter into or agree to the
Proposal relating to the Extraordinary Transaction and shall enter into an agreement with Customer or any of its Affiliates (as designated
by Customer) on substantially the same financial terms and containing substantially the same representations and warranties, exclusivity
(including any no-shop or other similar provisions) and indemnities in favor of Customer or any of its Affiliates (as designated by Customer)
as provided in the Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIQ SCRIPTS, LLC &ndash; MANGOCEUTICALS, INC.</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST ADDENDUM TO MASTER SERVICES AGREEMENT - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.4
<I><U>Right of First Refusal with Respect to an Asset Sale</U></I>. Upon receipt of the Proposal Notice with respect to an Asset Sale,
Customer shall have the irrevocable and exclusive option, at its sole discretion, to purchase, or to have any of its Affiliates purchase,
any or all of the properties or assets involved in such Asset Sale on substantially the same financial terms as provided in the Proposal,
as adjusted for the specific properties or assets Customer elects to purchase, or to have any of its Affiliates purchase, as compared
to all of the properties and assets subject to the Proposal. If Customer elects to purchase, or to have any of its Affiliates purchase,
any or all of the properties or assets involved in such Asset Sale, Customer shall deliver a written notice (the &ldquo;<B><U>Asset Sale
Proposal Notice</U></B>&rdquo;) to Epiq Scripts of such election within (i) thirty (30) days from the date Customer has received an Epiq
Scripts Notice, if such Asset Sale is with respect to all or substantially all of Epiq Scripts&rsquo; or any of its subsidiaries&rsquo;
properties or assets or (ii) thirty (30) days from the date Customer has received an Epiq Scripts Notice, specifying the properties or
assets it elects to purchase if such Asset Sale is with respect to less than all or substantially all of Epiq Scripts&rsquo; or any of
its Subsidiaries&rsquo; properties or assets (such thirty (30) day period, as applicable, the &ldquo;<B><U>Asset Sale Proposal Review
Period</U></B>&rdquo;, and together with the Extraordinary Transaction Proposal Review Period, the &ldquo;<B><U>ROFR Review Period</U></B>&rdquo;).
Upon receipt by Epiq Scripts of the Asset Sale Proposal Notice, Epiq Scripts shall (i) either (A) not enter into or agree to the Proposal
governing the Asset Sale if Customer elects to purchase, or to have any of its Affiliates purchase, all of the properties or assets included
in such Asset Sale or (B) amend the Proposal governing the Asset Sale to exclude the properties or assets that Customer elects to purchase,
or to have any of its Affiliates purchase, and (ii) enter into an agreement with Customer or any of its Affiliates (as designated by
Customer) (A) on substantially the same financial terms as provided in the Proposal, as adjusted as set forth above for the specific
properties or assets Customer elects to purchase, or to have any of its Affiliates purchase, and (B) containing substantially the same
representations and warranties, exclusivity (including any no-shop or other similar provision) and indemnities in favor of Customer or
any of its Affiliates (as designated by Customer) as provided in the Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.
<U>Procedure Upon Right of First Refusal</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.5
With respect to each Proposal for which Customer received an Epiq Scripts Notice and for which Epiq Scripts and its subsidiaries complied
with all of the applicable procedures and requirements of this ARTICLE VI (the &ldquo;<B><U>Noticed Proposal</U></B>&rdquo;), in the
event that (i) Customer does not deliver a Customer Notice or Asset Sale Notice, as applicable, to Epiq Scripts prior to the expiration
of the applicable ROFR Review Period or (ii) Customer delivers to Epiq Scripts prior to the expiration of the applicable ROFR Review
Period an Asset Sale Notice that excludes any properties or assets that were subject of the applicable Proposal (such excluded properties
or assets, the &ldquo;<B><U>Excluded Assets</U></B>&rdquo;), then, and only then, Epiq Scripts or its subsidiaries, as applicable, shall
be free, for a period of sixty (60) days following expiration of the applicable ROFR Review Period (the &ldquo;<B><U>Noticed Proposal
Period</U></B>&rdquo;), to enter into a letter of intent or other definitive agreement with respect to (x) in the case of clause (i),
the Sale Event contemplated in such Noticed Proposal with the Person or Persons subject of such Noticed Proposal on terms and conditions
substantially similar to, and in any event not more favorable in any material respect to such Person or Persons than, the terms and conditions
described in the Noticed Proposal and (y) in the case of clause (ii), the Excluded Assets on terms and conditions substantially similar
to, and in any event not more favorable in any material respect to such Person or Persons, as adjusted for the specific properties or
assets Customer elected to purchase, or to have any of its Affiliates purchase, as compared to all of the properties and assets subject
to the applicable Proposal; provided, however, that no such letter of intent or other definitive agreement shall provide for the payment
of any fees and expenses, including any termination or break-up fees, or any similar provisions with any Person with respect to Customer&rsquo;s
rights hereunder with respect to a new Proposal resulting from a Material Change (defined below) as set forth in <U>Section 2.1.6</U>
or that otherwise imposes limitations or restrictions on Epiq Scripts&rsquo; or any of its Subsidiaries&rsquo; ability to comply with
all of the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIQ SCRIPTS, LLC &ndash; MANGOCEUTICALS, INC.</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST ADDENDUM TO MASTER SERVICES AGREEMENT - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.6
If, during a ROFR Review Period or a Noticed Proposal Period, any change or amendment to the applicable Proposal or Noticed Proposal
is made that individually or in the aggregate with any other changes or amendments, is more favorable in any material respect to Customer
or purchasers (a &ldquo;<B><U>Material Change</U></B>&rdquo;), then such Proposal or Noticed Proposal as changed or amended shall constitute
a new Proposal subject to the terms and conditions of this ARTICLE VI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.
<B><U>Additional Information Rights</U></B>. Epiq Scripts will furnish to Customer such other information as Customer may reasonably
request in connection with any Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5.
<B><U>Term of Right of First Refusal Rights</U></B><FONT STYLE="background-color: white">. The rights and obligations of Epiq Scripts
as set forth above in this ARTICLE VI shall apply for the ROFR Term.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
V.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPECIFIC
ENFORCEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.
Each Party shall be entitled to obtain injunctive or other equitable relief (including a temporary restraining order, a preliminary injunction
and a final injunction) against the other Party to prevent any actual or threatened breach of this Agreement and to enforce specifically
the terms and provisions hereof, without the necessity of posting a bond or other security or of proving actual damages, in each case
in addition to all other rights and remedies existing in its favor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
VI.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION
BY REFERENCE.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.
<U>Sections 16</U>, <U>17.2</U>, <U>17.3</U>, <U>17.4</U>, <U>17.5</U>, <U>17.8</U>, <U>17.9</U>, <U>17.10</U>, and <U>17.11</U> of the
Agreement are incorporated by reference into this Addendum in their entirety, as if set forth herein (with the substitution of the term
&ldquo;Addendum&rdquo; in the place of &ldquo;Agreement&rdquo; where necessary or warranted).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
VII.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MISCELLANEOUS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.
Except as expressly modified by a term set forth herein, all terms and conditions of the Agreement shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2.
This Addendum may be executed in any number of separate counterparts by the Parties hereto, all of which when so executed shall be deemed
to be an original, but all such counterparts shall constitute one and the same Addendum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIQ SCRIPTS, LLC &ndash; MANGOCEUTICALS, INC.</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST ADDENDUM TO MASTER SERVICES AGREEMENT - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the Parties hereto have executed this Addendum on the day and date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;<U>Epiq Scripts</U>&rdquo;</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;<U>Customer</U>&rdquo;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EPIQ SCRIPTS, LLC </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MANGOCEUTICALS, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Sultan Haroon</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">    <I>/s/ Jonathan Arango</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sultan
    Haroon</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan
    Arango</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIQ SCRIPTS, LLC &ndash; MANGOCEUTICALS, INC.</FONT></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST ADDENDUM TO MASTER SERVICES AGREEMENT - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>mgrx-20230915.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaeDSbP9z5Z8aekhvWBwbUm6DyIseovKBCgt7GAWcaUB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:MGRX="http://mangorx.com/20230915" elementFormDefault="qualified" targetNamespace="http://mangorx.com/20230915">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://mangorx.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="mgrx-20230915_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="mgrx-20230915_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>mgrx-20230915_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>mgrx-20230915_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://mangorx.com/role/Cover" xlink:href="mgrx-20230915.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139926168657104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 15,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MANGOCEUTICALS,
INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001938046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-3841292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">15110
                                            N. Dallas Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dallas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">242-9619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 Par Value Per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgrx-20230915.xsd" xlink:type="simple"/>
    <context id="AsOf2023-09-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2023-09-15</startDate>
            <endDate>2023-09-15</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="AsOf2023-09-15">0001938046</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="AsOf2023-09-15">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="AsOf2023-09-15">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2023-09-15">2023-09-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2023-09-15">MANGOCEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2023-09-15">TX</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2023-09-15">001-41615</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2023-09-15">87-3841292</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2023-09-15">15110                                             N. Dallas Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2023-09-15">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2023-09-15">Dallas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2023-09-15">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2023-09-15">75248</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2023-09-15">(214)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2023-09-15">242-9619</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2023-09-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2023-09-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2023-09-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2023-09-15">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2023-09-15">Common     Stock, $0.0001 Par Value Per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2023-09-15">MGRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2023-09-15">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2023-09-15">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2023-09-15">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( /.$-5<'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #SA#573_HDQ>\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M:L,P#(=?9?B>R(G'H";-I66G#08K;.QF;+4UC?]@:R1]^R59FS*V!]C1TL^?
M/H$:':4."5]2B)C(8KX;7.>SU''-CD11 F1]1*=R.2;\V-R'Y!2-SW2 J/1)
M'1!JSA_ (2FC2,$$+.)"9&UCM-0)%85TP1N]X.-GZF:8T8 =.O24H2HK8.TT
M,9Z'KH$;8((1)I>_"V@6XES]$SMW@%V20[9+JN_[LA=S;MRA@O?GI]=YW<+Z
M3,IK'']E*^D<<<VND]_$9KM[9&W-:U'P55%7NYI+L9+B_F-R_>%W$W;!V+W]
MQ\97P;:!7W?1?@%02P,$%     @ \X0U5YE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M1S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ \X0U5Y>*NQS
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M7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @ \X0U5R0>FZ*M
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #SA#573_HDQ>\    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #S
MA#57F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( /.$-5<M:FG#G 0  /\1   8
M  " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #S
MA#57GZ ;\+$"  #B#   #0              @ '@#   >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( /.$-5>7BKL<P    !,"   +              "  ;P/
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( /.$-5>JQ"(6,P$  "("   /
M          "  :40  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #SA#57
M)!Z;HJT   #X 0  &@              @ $%$@  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " #SA#5799!YDAD!  #/ P  $P
M        @ 'J$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"
(   T%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
    <File>mgrx-20230915.xsd</File>
    <File>mgrx-20230915_lab.xml</File>
    <File>mgrx-20230915_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "MGRX",
   "nsuri": "http://mangorx.com/20230915",
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "schema": {
     "local": [
      "mgrx-20230915.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mgrx-20230915_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgrx-20230915_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://mangorx.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-15",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-15",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001493152-23-033356-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-033356-xbrl.zip
M4$L#!!0    ( /.$-5=.\B]UQ30  !]$ 0 *    97@Q,"TQ+FAT;>U]:W/;
MUK7V=\[P/^!DVH[<@67)MMS6<CV'ENB8'5G2B'32S)GS81/8I!"# (N+9+V_
M_EVW?0$(RDHB)Y0.VYE8)(%]77O=U[/??)A\/'G;[[WY,!P<P[\!_N_-9#0Y
M&;Y]\XS_A5^?R<]OWIT=_Q2,)S^=#/_YW2S/JM?!_MZR"B;)0I?!J;X.+O*%
MRD+^(@S&NDAFW\&+\.KY+WWO,%BH8IYDKP-\=.\PJ/27ZJE*DSE\%>FLTL5W
M;]^\/SN=^"T_G:E%DMZ\_EK;]&R9_#_-0X&6WKW]2S8MEX=OGKV#N6.[\,_Y
MMQA\D<POJWL>^_#+93)-JGYO?V]W_]M/X4&O_S<9_-'P8C(8G?9[1V>G[T?'
MP]/):' 2G)]=3$9GI^/@['TP^3 :!\-_?QB]&TV"#X,?AL&[X? T./LXFDR&
MQ\'@]#BX&)Z?#([@PX^CR8?@+VG\GSH__)^__O6O__N7@O[>#<:?CCX$W/[[
M$3PY.GU_=O%Q@+U HV-N<_COHY-/Q\/C?N_]Q=G'9L_OAD>#3^-A '_"MSNC
M)\'IV22 %H87.&(<QLX(OIU\&,)XOA^-)Q<#6*:C3^/)V<?!Q>CD)WIF<#3Y
M-#B!#Y.+X6 RAL<'D\9@8"SG%Z,?H-U^[^PB\)=E]X'N\<,F4"##3R>3T>GW
M_=[@^XOA\"-LQ@.=R^^U$3_7997,;N3+)(LU-KJW>Y!D]SPC/*+$.V2/@L86
M!3O595(:A@"/O_GT=C OM%[ @-X\^_06'Q(6\22 )Q<JU@&]LW_P9OSI_&UU
M^>89_AO$ZB;(9S"49:474UT$S_>>O\#V=;/YX6RFHRJYTOW>L:ITNY,PF-X$
M*HN#J:ZNM<Z"CRJ;YY&NJR12*<QUE$6[8:""B?ZBRB#*BV5>J"K)LXZ^CO+%
M4F4WJWU@!\-E\I]@'!7)LBK#?N_DY,@UFR:+I-(Q_*NF29I4-] 1-=7925;6
M::4Z%FQ'J^@25P5?DL%0W^X=7-1"SW110'=5WN]=ZD(G60"#4,U^SE51M:?"
M,XGR-.4U36_\Q@+7ULJHL;5$E^TA[SX*NC?'^,'QGQ_[O5$P"4#0!F/X_Q#^
M_O!ZRTLW@:9P=SX,02<9XY2 8?AG.M9E4D!S<.;R::7@S.&OI2ZND@B^!@[@
M3GS8Y@#>R\LBOTJ PT;\:Y+-72/PL]]EO<RI%QB(+A:E,((L3I 7EG+TU0Q^
MA"8JF$]176Y/]X9-!8CJ].Q'(*8)DA;HN$,BK@ ("$D 2$%DF\B09:$728DM
MXB=E)+79;GP)J0^X/Y)##@\5P3S/^>.52FLU376SZ1 D1J1!".(S_5Y9SV9)
ME.@L(G%^?9F !$NX Y3,T><LOTYU/-<Q#T($"3T )$IC0HDC([;B/D!ICS_,
M0%KEU^7K1[&!#U;2#,!^/#H!$VKT4(VFX>GW@^])DSV$\S.\^'@8C(<7/XR.
MAN,'.J-')C'W=_=W8>R?WHY%A*&RN1N<UT59H]P3@79W\14V!*!P))W-U1S&
M=8N Y2?[/15%8)V405D#3^/WD'N&ON1=7JIBH:*;3A','#9#A@8\^3JI+OT1
M_:4H48<N@WF:3U4:Z"_P;8E/ZAF.OPR9Q2K4^%699\",45__3ZU+-#9@,@V=
MHBZP<_QJ DO$#!4XL;7/.FP1?Z6W:OT&3V5_]SF?#=Q:/A<>P9:7*DW! H9!
M"F$B)9C-)7JN861%P"H@V-X@6E?I0TUSD+NWF.!!IP4.% KGI]46#PG4#U1N
M$R)I:".HLRI):0Q:%6F"0YH%.^I),,/F=PZ>!#?P RQ$7@0[TR=TV.%<([G#
M,9!#%V.#(I""T6@4PM1!1>CW5H=NEFM+W!L\E?W=%TS< ]#T(JO XEOL><DT
M#-'(@PGQO!:S1M(@39=XLRZ ?R[HW3@I(V#1<QW,%/#?69VFS#;MZ6"5=:%N
M@(KZ/<=>9]"B,%C;&7^'XT)AA/^VF#!U64,7JJXN\P(F&<,A #6\A*53>(;*
MEG]G94)T<OH](V :8\71)>BL<4<:_34P2]@P.L+0/[PYTR4*$A JL/ZP>H^8
MY&$R__7T:? ^T6G\&JR+N0:]#C<QB_#%P^!L22K":^QHS*+X,/@!;!O\.7CZ
M5,*-;XY'/YA1\E2?3O.JRA>O@U?+ZC"8Y@4LM_WN70JF3;"_>P"K4>9I$L-$
M)X-WP)".AB<GYX/CX]'I]__\;N\[^CP^'QR9S]*'M(>^.+4L82SFKT-0%.+J
M$B>]]^<NQ6]R8=JXT@6Y.<T^5/FRN3&IGM$;Q[]\N[U!W.<>'CDUR7,<RXY.
MCO$_%[_/%.]S5DAV@4^'A@(/@\G-$AX;%&J:1(?!J5IHIM+3'&EOWW_IF7D+
M?T$VL;^_NC3/B,K@7Z#7#M*=@JKX^>E4 P.$CI9T'(2<8>F(EF'BYTU*IT/M
MSM=YLW5_A#11.C/WP$0>J#GTC>WK!VM@8]!H=#R\H+ KV-C#?Y\/3\?#\6$P
M.CT>PM\8=<7XZ^1B<#0YNX"S,?CWUOC>#-GZW!C?1[ZSCS6NXZ]9EB':VP$J
M_)ZF@MH)6ZDM;8WU%M14\(T(;(Y,H4^R:=+W>_1<I3[KS&A9QG>X;+@$FB/Q
MM3$V0I;J9L7$YU_8P \#"@PNECHK:=9;5^-OF\K^_9/F?K\W .M5/R6E&W:4
MC$P@Q#^].@CW]O9"_(Z<U>AEP7@*4,W._MX3C#.O<RZOFHNC#(@/M.9S[J!M
M.3Z&U7Q49/&\WVOPJV"J2N YXN;(:DHL@,T_!P.,(O?XS'F2IF4PSM,X].(+
MH?,N5)>J"K*<_7[-N(KQM("1IYTSH]][GQ1E%8P5$.!.K&<44B&GQ),_A)D\
M'IJY;ZZXDSSI]RB3C626!OOB9I4\B#HD'0-(I+FC;9N_NBSR>GZ9UY41D452
MY= L=A"I\K(=0",W-0>$'=V$O@-W":///1=$BW$Y+]I^B39_!K\4I2IN[LSH
M?M*J .M7^-R*_S?L]Y(9-'SS.#;]4='O+R#@>R'48#V=]GMM0KT;/3KZ?8Y:
MX*^EW^=;^GUP4P'ZW6@"OAM!.@)^4?P& GZQ)> '-Y6=Y&J3Z?=N].CH]V5U
M^>OI]^4=Z!<M[T>Q\8^)AC>:A.]&DHZ$#^[R?!@P/:XAY7[O8!TML^\(WR*:
M=\]A'LA<4\Z<3>UHZ=5AT%)4Y O'^*GQUF&"P^.G:(>KV=BXB.77!]Q\K&.X
M+7]'1T\N7@-&KMZ03)%'=+;OW^W72G_@X]G:MGYOH556!M=YD<;7<%K#0']!
M7R@=8R2"3QD5-(PK.#LE)IA&:4U9)0D2DC2+OEB*..=ER1'GTM+><5)611)5
MG,R<UHMIHAYQ&/J!3L4G%N+/_1XRC1:Y!$PM-G6('&3X:48L/<H7"UU$R$A*
M](!U.]SR**H+RHEK"([=X+V07*D^T[M1JN"G&^""6=YF80W_V\R^R)TB>^_H
MV$D*7P)E\#*WULKQD,:Q,>J\W[.]8X<='90H)Y<@Q J3H^BY W-)T?@9)%X9
M)YP*R)G6L(SMQ7@<5/5(#XB_]4 5N/?=!X7\ADN?4.*BG@=+5*K*+J6*J09F
M0JESZ':F9Q<P2:1':6K*X30%O<28$Q'$>014 P<%:1G;%>TL*'2E@.8E.179
M='XE6EB4UQ@-I9H!GR8Q$4H7&I.)J%6;G=J81U+"P:E<'I)_!&$8,QX\SK9\
MQ+1\>\[1\VUZT3:]:#/2BYYOTXNV(NTVD88F_AK;@)0\U>$62$3C,19_Z*J^
M5%35*J4JA4B#\7I;D8):+E,X>ABS9P\ VZUQKDG&]'ML<^ANM8YZYWX;[<O;
M9@ =+HG OMCQ&\ZMGI9T4"JNCL8TE#@TPX'1A\&TKJ@3*?L.N?H:A@BL!P\6
MB-^ZR$HLE?N9,T[A;\Q$1ME+7T_9K.+4Y"GP^M*KP.-.,8<F5<3*0#_HT#U"
MDT.37ZLL$E-,Q4A&XEHPNQ&!J"9S#AJ*X.<<U/6UVBSO.V@"Y3)/4IQ=K!:*
MZO?RND+]'_^: @GH2H>8,8V3Q:A[P>._3DJ-ZP]=XZ.X6'D&HR '3-Q2=EAY
MP$1OZ!$5Y2@"R87S82]%"4L&5%272086)B@C,*G$3!;W &L+P'0M2U(_>';H
M!8+S W_#'R5H];$JXG(WF+2Z%BMF61>P$27J6=#T6DO"D3DYQFXA%=Y6&#9L
M;!B8!:*BAD(GBRG80;P9RO9=F&AST_UR08VN A*L9CF!FDAG"5K% JA\-N,(
MLUH@T9E)M<PIE0(_CV^ D2=Q5[42:7,7,K$.8@$2G*LD RUU5L,DVQZG1ZP"
M/LRI/#=E1(.(>!$R%S"_F9-8JAAE: _[A! &JQ['[>9N5(X.;NU^O_<.B\ R
MW%=)@A(7#6P?<L%@ >]=>D[YMI<<"<'%!!R#:[> C%YS,ZW"PY"]^H8[72><
M@MF6^2U.!"I NPL:!O+$-9&)#FE!?5 56QE=ZKA&H]2FA-W65K<V8;48U!1V
M@S$9YF;$-+&IMHF'P'A]F!887%%(+1M(;.5F]Y]:%;!N(#)@:"!%5M8/JU0%
M".9?*JM1FNT?X"$<@(!*Y>]_8941_XE[=@8V.R:[\3=VZ206(EV"C-3$R8]A
M8I0;]V*_K,+@HP(A)'__J\YT\&*/8BJQ!\^#7Z$L*Y<N+C%M$UL;Y,?.6=!^
MR $AWX&>*=N,&HQ9@18-R-JXK?$]:^10;.?M29A'.F-B,/FBJ+P8'^(,_\,[
MD^79TW=&PSC&;.'2V^FFS]&D%L))#OQWO&G0RV5%18M^SUSI-4NP+,M^#TW:
MG.A^SW9% CFWWD&J@42*I="7<;I(X,P@'Y%J@THD3SU5_KD7"K#N^7:C?TP<
M9\O+U_+RY_W>:%4AHT/=8)V=&>]2.ZB8#)F*=47BGBKCS5&+ZE3Y>"&-EBE4
MVN\UP;ZLWK AD< M!:VEH!?]WOLNK=PQ-# 2T%9 9VY%X (M:YVJ.CI-(1*:
MUAX"(@+68NV$G0; 6)-^G'G:D3+"#7K/N*$RD!S;;VH^+_0<.6%K8A);^HH,
MN1%;$Z1'L>*AD&IVVZ\X(6+3MG< M@2_01-!@G_9[PW2U&EH+6IVM4=-JI*=
M3=7UK$Z19K15'QI1</QRL(#^(X7O) L,P\ /6.U]I9*4M$#RW/1['M "$#&H
M3,DLD;)MU Q]"HMUBJDK[!#P-$@,'%8EH7W-,_V'0R$]'L+[)B4%HUEPE2@0
MTL!:JD)EY0QC;'ZA&OV$OI*BEH";55P[805\V &@A5@O\S)!PP+]1FSZU((&
M-V>$#&RFW_M*.^ZCC?!-=:9G274()/<H-N11T99'7&#2HC_12,$X+M#X<%D'
MJD*_IJAS9(6P/QGLA#(G6$_'B0@R S,6KHL$7T-?*CH_&SQHF]RU43P39=Q!
MOX=/H=8E,@IH@()Z*%?0I)W"B!0SF!:2K!6 7CY72'8%IG-2,$.2-KT"RXX\
M0B D_073 LKTQ@*5&.'V:+6BVX/^+[9!_VW0?S."_B^V0?^'+CB^0>!'(+8N
M-'K,.7PZ  E0!1=X"X@/K25(5GB2)!J<&"?H9ZV7J'G6!8&S$F##8HF!8/25
MVX:G>?Z9I(]14J,<*+ @3[%"<*LU]=AWP# T\8GJ.F>H."\2L1N@^></),ZC
MFF765V+IW+VUR<IZBH%[?%A_4<91BF*3W=_X=Y0O;TB HI.$5A)U*E*U,IWZ
M &!-)1S&]4S\*C"W GW$185HD]@&QM +LVRJJ=XWFMD-AIRP+=:KOA)YK1C
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M&=2&3>7Y[BN!UD?!MLJ=%NHSU10T<+S)NPYTI(H": N/-S$928^S5U6H+W3
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M+)2KA76LD1XI)F;ROR7RQ$E<HOO9N-#U)6..DPDM.;><J$KD36F@T&H=21J
MRN8F%+D(=O3N?#<,EI<W)0&>HHU/&6+8;8T9#9>J '6Y2*XT(:QA>9Q:(IQU
M%>T^>0T$0N9<=9G'F":@H\LLP5QCRK7 B5#4+0;#GK!-- &AD ;.J\4'$YXE
M6N%D;'@43BVLGJ8C;K]<I@K_6>2Q3DO[$H=R^2<'8\:?51P_A9V9:85E^CA
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MO?&_TU!O$E2N: 4!+\B<: A6,F;NLO;*,1CR_]O9 6E#Q>$+D'"FZA :^*M
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MNJ'I%1[PWN[3!DUKY,"7,EY"U&0\D&A&4!^#:YE,T:"@-?2:_8F HF[40H*
M#/24P1L3]!4*50RL,P,B-/8!_ ..B]  _LP<)$#_>IYJ)S'@U^"?-B4F4+.Y
MBY8'78P!J?-&L$_,,[0%$<#&AW%@OIVGK57HQB>;51]54.1IMN#=(P.CJ;8.
M)@HM(SHML@"GGH<%>SNQ$DF:P=<EO5YDFG2JXT+#2:0U"QP:+3;=#K&/MI%;
M2U=;Y^#@@ZY%@9A+C59=Z!U,^&83K_" ]W;WZYOXM4H42J8@,9_?)@T/8$ V
MV@<V0+I 86,$9BE0%A+JL$ <M+<?[NP3O>%?!^;LP#<O80]D$>VMON$#XB@
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M:9(:N71>9/.4:9W4K!E%GZ)JFA2BSAN"M:.U3:M+O2CE3<J8RW'BI TAK_"
M]W;_52=DI[I8KEDQ&@P\[F8JOT[A4,!K>'K@QX H9T4LS:F=J^ Z2>-TNH 3
M, T*XX5/ERDZ,4KPA=*P$JB,M/AH'YVS)Y -BJQ\QC4<F6/,]<5/VY)G,J+F
MS%U6('(J%SI&[7W7LE42P9&[Z)5:(7C/ZI&JVB$?9/@1FIN-L\(#WMO=>U+?
M.1>M!JK2,)N@7P(0_-PX; (1SE,;$&+Y?AS)<12CHAVI&%[KB2GCD4^?$W 4
M9#!\VB7S+%)Y:A[^,XT )"$A%QE@30<#??LO$GCI>@!MI- +#DDNQF'$@?>
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M<:]M1*8RCU+U>K?8166L$F$%](U+(T]=CG4O->W&#XEE12N4!41'6)8!'F7
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M"N5JH;J>Z*3@"2W5$?Q>[-HW/^UGHU"KA/U,3$X:4WS=YEY$<5V,D3L<$U[
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MI_E20\^TO!:")LY:+R^A= "6DPI*L@LR,*W76)@@/T;"(][3D%C!*2LJ%D;
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MT9;BN+<##+_ M?"Y[>(.4:/?!JZ5HW*L#8+F8&@ON';!M>/V3<*2)DD./6@
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MOJW.!.#6K7F:/(%O!WXB:)5G)V)H:'84+%,??X3VNMW/JQJ!%&5U&PUXK H
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M>.0ZW]]N5JS+L\^#\^,/SLVGM4_M\LUF\\\#:_/H8O#NG23)_P-02P,$%
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MTT0T<VR !9=EH#)N@TSY'H+8"4U=&X3AX^BUP :8>HS'>B034+5I-]1B^1
ME0^,!SV8X<A7>?R,L$]F!%P#2<P]D'K&1(@=."R6SRFFE*EQ5CN56;0M#(F:
MU\*@3+J_+<Y\^*821_J@]FEG!.VSNDQ="08B;L=(CVM:N9H+,T))$CE;'QN9
M>EDB7:0Z)LRVM0TN*T4"W*_T)CF''(2B)Q4-E"'C9Y##7 ?[3N2?15WE=XB9
MV?/W6'K!^1:-8(:2[6OI.>D8@NC[S\AL<PZSCA%X/#;S=OY095?4'.40'>'
M]B4]VGY36>!< G.GI%*Z'90("X%+HH9Y[0I(4R=2TY_6PB =1QC(^H>5^WAZ
M:N6* OY_+'F@]<NUMJW-Q5+/V\O75N4R+A$M+?&A*S2]_ ?,2:0.4/23F?-,
M;3+MFEFW*[%P5YF>DL3J#9R61,X[(XD]%_FN^&(?7!^2$3HVZ)X/PL&@.SD6
M^%+DEK-36/]\_$4.B<Q)26RTTY7<TA):M&:J/M;M_>G\B9D\B[.&P&$1E?S]
ME$%8I^0/YW5C]>$_KA$Y/FV"_B]P;M@SIJ <?-<(M*U431U_ U!+ P04
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M?Q;0!0%*C[G67=M"W@#%TPQTR;(DVZOGZ6ZVFQ41EL:U):[8@,QI)LSR(%@
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M-[BWTQ;?N%_N#:QVR_]02P$"% ,4    " #SA#573O(O=<4T   ?1 $ "@
M            @ $     97@Q,"TQ+FAT;5!+ 0(4 Q0    ( /.$-5<>C:C=
M0B,  +T1 0 *              "  >TT  !E>#$P+3,N:'1M4$L! A0#%
M  @ \X0U5[C]FYK1(0  ]O4   L              ( !5U@  &9O<FTX+6LN
M:'1M4$L! A0#%     @ \X0U5RK>_G@G P  X L  !$              ( !
M47H  &UG<G@M,C R,S Y,34N>'-D4$L! A0#%     @ \X0U5RZU(T7]"@
M@(8  !4              ( !IWT  &UG<G@M,C R,S Y,35?;&%B+GAM;%!+
M 0(4 Q0    ( /.$-5?'2FR550<  --7   5              "  =>(  !M
J9W)X+3(P,C,P.3$U7W!R92YX;6Q02P4&      8 !@!N 0  7Y

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
